5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole-3-carboxylic acid cycloheptylamide | 1040397-94-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole-3-carboxylic acid cycloheptylamide
• 英文别名: 5-(4-chlorophenyl)-N-cycloheptyl-1-(2,4-dichlorophenyl)-5-methyl-4H-pyrazole-3-carboxamide
• CAS: 1040397-94-1
• 化学式: C₂₄H₂₆Cl₃N₃O
• 分子量: 478.849
• InChiKey: APPOYQHOHQGQFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1H-pyrazole-3-carbonyl chloride 、 环庚胺 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-5-methyl-4,5-dihydro-1 H-pyrazole-3-carboxylic acid cycloheptylamide
  参考文献：
  名称：

  Substituted pyrazoline compounds with ACAT inhibition activity, their preparation and use as medicaments

  摘要：

  本发明涉及取代吡唑啉化合物、其制备方法、包含这些化合物的药物以及它们用于制备用于治疗人类和动物，特别是在脂质代谢紊乱方面的药物的用途。

  公开号：

  EP1947088A1

文献信息

• SUBSTITUTED PYRAZOLINE COMPOUNDS WITH ACAT INHIBITION ACTIVITY, THEIR PREPARATION AND USE AS MEDICAMENTS
  申请人：Torrens-Jover Antonio

  公开号：US20100069364A1

  公开（公告）日：2010-03-18

  The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.

  本发明涉及取代吡唑啉化合物、其制备方法、包含这些化合物的药物以及它们用于制备用于治疗人类和动物，特别是在脂质代谢紊乱方面的药物的用途。
• Substituted pyrazoline compounds with ACAT, their preparation and use as medicaments
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1950203A1

  公开（公告）日：2008-07-30

  The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.

  本发明涉及取代吡唑烷化合物，其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类和动物，特别是在脂质代谢异常症方面的药物的用途。
• [EN] SUBSTITUTED PYRAZOLINE COMPOUNDS WITH ACAT INHIBITION ACTIVITY, THEIR PREPARATION AND USE AS MEDICAMENTS<br/>[FR] COMPOSÉS DE PYRAZOLINE SUBSTITUÉE PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DE L'ACAT, LEUR PRÉPARATION ET UTILISATION COMME MÉDICAMENTS
  申请人：ESTEVE LABOR DR

  公开号：WO2008087030A1

  公开（公告）日：2008-07-24

  [EN] The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia. Formula (I).
  [FR] La présente invention concerne des composés de pyrazoline substituée, des procédés pour leur préparation, des médicaments comprenant ces composés et leur utilisation pour la préparation d'un médicament pour le traitement d'êtres humains et d'animaux, en particulier dans le cas de dyslipidémie.
• Substituted pyrazoline compounds with ACAT inhibition activity, their preparation and use as medicaments
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1947088A1

  公开（公告）日：2008-07-23

  The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.

  本发明涉及取代吡唑啉化合物、其制备方法、包含这些化合物的药物以及它们用于制备用于治疗人类和动物，特别是在脂质代谢紊乱方面的药物的用途。